In vitro-diagnostics. in the Capital Region Berlin-Brandenburg

In vitro-diagnostics in the Capital Region Berlin-Brandenburg

Germany s Capital Region Berlin-Brandenburg Your Partner for Next Generation in vitro-diagnostics Berlin-Brandenburg covers the full range of the biotech and pharma value chain, from substance and process development to clinical research, production and services. In vitro-diagnostics and bioanalytics in Berlin-Brandenburg means:»» About 20 excellent research institutions focus on the identification of new biomarkers and new platform technologies for diagnostic tools.»» More than 80 small and medium enterprises (SME) as manufacturer or supplier cover a broad spectrum of highly innovative diagnostics. Berlin-Brandenburg develops solutions for next generation in vitro-diagnostics and bioanalytics like sensor-actor-molecules and autonomous biosensors, genome-, proteomeand glycan-based multiplex analytics (microarrayand bead technologies) and metabolomics platforms for new biomarker strategies.»» Berlin-Brandenburg is the place for implementing clinical validation studies. Germany`s most diversified hospital landscape with the Charité Universitätsmedizin Berlin has access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. Customers from research and industry may have access to advanced biobanking infrastructures. The Berlin-Brandenburg Center for Molecular Diagnostics and Bioanalytics (ZMDB) is the platform for technology transfer and supports cooperations between science, clinics and industry. The ZMDB is your interface to get access to Berlin-Brandenburg s expertise in in vitro-diagnostics and bioanalytics. Basic Research Applied Research Identification of Biomarkers Genomics/Proteomics/ Glycomics/Metabolomics Validation of Biomarkers Microarrays Lab-on-Chip POCT Biosensors Automation Product Research & Development Production Approval Reimbursement Marketing Clinical Studies Validation of Biomarkers Biobanking Metabiobanking

In vitro-diagnostics in Berlin-Brandenburg Selected Companies 1 7 12 13 16 20 40 41 29 25 8 33 42 30 38 35 4 14 31 23 44 26 9 15 34 36 24 43 Berlin 22 27 2 6 18 19 16 21 39 20 32 17 28 37 16 3 20 10 45 Brandenburg 5 1 8sens.biognostic GmbH 2 Alacris Theranostics GmbH 3 ASTRA BIOTECH GmbH 4 ATLAS Biolabs GmbH 5 Attomol GmbH 6 BIOTECON Diagnostics GmbH 7 BioTeZ Berlin-Buch GmbH 8 BST Bio Sensor Technology GmbH 9 caprotec bioanalytics GmbH 10 CellTrend GmbH Chipron GmbH 12 CONGEN Biotechnologie GmbH 13 E.R.D.E.-AAK-Diagnostik GmbH 14 Epigenomics AG 15 Epiontis GmbH 16 FILT Lungen- und Thoraxdiagnostik GmbH 17 GA Generic Assays GmbH 18 GILUPI GmbH 19 GlucoMetrix AG 20 Glycotope GmbH 21 idoc Institute for Telemedicine and Health Communication GmbH & Co. KG 22 in.vent DIAGNOSTICA GmbH 23 Institute Cardiac Diagnostics and Therapy (IKDT GmbH) 24 JPT Peptide Technologies GmbH 25 Labor Berlin Charité Vivantes Services GmbH 26 LGC Genomics GmbH 27 Limetec Biotechnologies GmbH 28 Medipan GmbH 29 Metanomics Health GmbH 30 MicroDiscovery GmbH 31 Minerva Biolabs GmbH 32 peptides&elephants GmbH 33 PolyAn GmbH 34 Proteome Factory AG 35 Provitro GmbH 36 SCIENION AG 37 Seramun Diagnostica GmbH 38 SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin 39 Signature Diagnostics AG 40 Source BioScience imagenes GmbH 41 STRATEC Molecular GmbH 42 Strix Diagnostics GmbH 43 Surflay Nanotec GmbH 44 TIB MOLBIOL Syntheselabor GmbH 45 Zentrum für molekulare Onkologie GmbH

In vitro-diagnostics in Berlin-Brandenburg Research Institutions 12 16 6 4 17 2 5 9 13 14 15 1 Berlin 7 8 20 3 18 10 Brandenburg 19 1 BAM Federal Institute for Materials Research and Testing 2 Beuth Hochschule für Technik Berlin University of Applied Sciences 3 DIfE (German Institute of Human Nutrition) Potsdam Rehbrücke 4 Charité - Universitätsmedizin Berlin 5 Deutsches Rheuma- Forschungszentrum Berlin 6 Fraunhofer Institute for Telecommunications Heinrich Hertz Institute 7 Fraunhofer Institute for Applied Polymer Research IAP 8 Fraunhofer Institute for Biomedical Engineering IBMT 9 Humboldt University of Berlin 10 IHP GmbH - Innovations for High Performance Microelectronics Leibniz-Institut für Molekulare Pharmakologie (FMP) 12 Max Delbrück Center for Molecular Medicine Berlin-Buch 13 Max Planck Institute for Infection Biology 14 Max Planck Institute for Molecular Genetics 15 Max Planck Institute of Colloids and Interfaces 16 Physikalisch-Technische Bundesanstalt (PTB) 17 Robert Koch Institute (RKI) 18 Technical University of Applied Sciences Wildau 19 University of Applied Sciences Lausitz 20 University of Potsdam

In vitro-diagnostics in Berlin-Brandenburg Overview Companies 8sens.biognostic GmbH 1 1 Alacris Theranostics GmbH 1 AptaRes AG 1 ASTRA BIOTECH GmbH 1 1 1 ATLAS Biolabs GmbH 1 1 Attomol GmbH 1 1 1 1 BIOTECON Diagnostics GmbH 1 1 BioTeZ Berlin-Buch GmbH 1 1 BST Bio Sensor Technology GmbH 1 1 1 caprotec bioanalytics GmbH 1 CellTrend GmbH 1 1 1 Chipron GmbH 1 CONGEN Biotechnologie GmbH 1 E.R.D.E.-AAK-Diagnostik GmbH 1 1 Epigenomics AG 1 Epiontis GmbH 1 FILT Lungen- und Thoraxdiagnostik GmbH 1 1 1 ifp Institut für Produktqualität GmbH 1 1 1 1 GA Generic Assays GmbH 1 1 GILUPI GmbH 1 1 GlucoMetrix AG 1 1 1 Glycotope GmbH 1 idoc Institute for Telemedicine and Health Communication GmbH & Co. KG 1 1 in.vent DIAGNOSTICA GmbH 1 1 1 1 1 1 Institute Cardiac Diagnostics and Therapy (IKDT GmbH) 1 1 JPT Peptide Technologies GmbH 1 1 1 1 1 Labor Berlin Charité Vivantes Services GmbH 1 1 1 1 1 1 1 1 LGC Genomics GmbH 1 1 Limetec Biotechnologies GmbH 1 1 1 Medipan GmbH 1 1 1 Metanomics Health GmbH 1 MicroDiscovery GmbH 1 1 1 Minerva Biolabs GmbH 1 1 1 peptides&elephants GmbH 1 1 1 PolyAn GmbH 1 Proteome Factory AG 1 1 Provitro GmbH 1 1 SCIENION AG 1 1 1 1 1 Seramun Diagnostica GmbH 1 1 1 SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin 1 1 1 Signature Diagnostics AG 1 1 Source BioScience imagenes 1 1 1 STRATEC Molecular GmbH 1 Strix Diagnostics GmbH 1 1 Surflay Nanotec GmbH 1 1 1 Thermo Fisher Scientific B R A H M S GmbH 1 1 1 1 1 TIB MOLBIOL Syntheselabor GmbH 1 1 1 1 1 Zentrum für molekulare Onkologie GmbH 1 1 Clinical Chemistry Immunoassay Molecular Diagnostics Hematology Coagulation Microbiology Point of Care Testing others

science In vitro-diagnostics in Berlin-Brandenburg Overview Research Institutions Basic Research Identification and Validation of Biomarkers BAM Federal Institute for Materials Research and Testing 1 1 1 Charité Universitätsmedizin Berlin 1 1 1 1 DIfE (German Institute of Human Nutrition) Potsdam-Rehbruecke 1 1 Fraunhofer Institute for Telecommunications Heinrich Hertz Institute 1 Fraunhofer Institute for Applied Polymer Research IAP 1 1 Fraunhofer Institute for Biomedical Engineering IBMT 1 1 Humboldt University of Berlin Systems Immunology Lab 1 1 1 IHP GmbH Innovations for High Performance Microelectronics 1 Max Delbrück Center for Molecular Medicine Berlin-Buch 1 1 1 Max Planck Institute for Molecular Genetics 1 1 1 Max Planck Institute of Colloids and interfaces 1 1 1 1 1 Physikalisch-Technische Bundesanstalt (PTB) 1 1 Technical University of Applied Sciences Wildau 1 1 1 University of Applied Sciences Lausitz 1 1 University of Potsdam 1 1 1 1 Assay Development Technology Development others

8sens.biognostic GmbH Foundation: 2000 Employees: 10 8sens.biognostic GmbH design, develop and produce in vitro-diagnostica (IVD) up to CE approval. We offer: custom-made development and production of immunochromatographic lateral flow tests and microtiterplate-based assays (ELISAs, etc.) as well as production of antibody conjugates (colloidal gold, latex, dyes etc.) for research and production. Our key business activities also cover novel protein-based macro arrays for multianalyte detection (e. g. panels for heart attack, heart risk and TORCH) as well as adaptable reader systems for easy quantification of rapid test and macro array results. Market Segments Lateral flow assays Reader systems for quantification Development on demand IVD-orientated nanotechnology Rapid tests QuickSens h-fabp, ctni QuickSens CRP, hs-crp Reader system QuickSens Ω100 8sens.biognostic GmbH Robert-Rössle-Straße 10 13125 Berlin Germany www.biognostic.de Volker Landorff landorff@biognostic.de

Alacris Theranostics GmbH Foundation: 2008 Employees: 15 The company is based on novel translational medicine/ systems biology technology developed at the Max Planck Institute for Molecular Genetics in Berlin coupled with preferential access to the world s most cost effective sequencing and genotyping technology. The scientific founders are among the world s foremost experts in sequencing technology, systems biology and biomedicine. Alacris Theranostics offers its services internationally in Europe and North America. Cutting-edge next generation sequencing technology Genome, epigenome, and transcriptome sequencing Proprietary technology platform ModCell Identification of diagnostic markers In silico simulations for the study and evaluation of signal pathways relevant for cancer Simulation of drug effects Stratification of cancer patients for their clinical trials and for biomarker discovery Alacris Theranostics GmbH Fabeckstraße 60-62 14195 Berlin Germany info@alacris.de www.alacris.de Dr. Bodo Lange Biomarker discovery Computer modeling for cancer drug validation Non-invasive cancer genome sequencing Partner in the IT Future of Medicine-project within the FET Flagship Initiative - Partner in the OncoTrackproject within the Innovative Medicine Initiative

AptaRes AG Foundation: 2002 Employees: 18 AptaRes is a leading biotechnology company providing oligonucleotide aptamers as an alternative to common antibodies. AptaRes is the sole owner of the proprietary Mono- Lex procedure for Aptamer selection and its applications. We offer high resolution bioanalytics and the technology for downstream processing for immunoglobulins using an innovative IgG Fc-specific binder (like protein A). A quality management system ensures transparent, validated and reproducible processes. The bioanalytical service includes high resolution 2D-gel electrophoresis, mass spectrometry, N-terminal Sequencing, functional tests and more. The protocols are custom tailored to validate product identity, quantitate side products, and validate processes as well as binding specificities of antibodies and aptamers. Market Segments Aptamer selection and applications Bioanalytics Aptamers Antibody Purification Protein Identification / Proteomics N-terminal Sequencing (Edman- Sequencing) 2D high Resolution Electrophoresis MALDI-TOF-MS Analytic Structure Validation Host Cell Protein Analysis (HCP-Analysis) AptaRes AG Tempelhofer Weg -12 10829 Berlin Germany Phone +49 30 24537613 Fax +49 30 24537622 info@aptares.de www.aptares.de PD Dr. Andreas Kage (CEO) New Aptamer based active agents New Aptamer based applications

ASTRA BIOTECH GmbH Foundation: 2009 Astra Biotech GmbH is a quality-focused company with its success founded on dependable science and strong relationships to develop IVD-compliant, CE-labelled in vitrodiagnostic assays for laboratories specialising in multimedical fields or in education. The product range available includes reagents for detecting and calibrating human hormones, genetic diseases, tumour markers, allergens, antibodies, and recombinant proteins. Market Segments IVD Molecular diagnostics Immunoassays Research on brain stroke, heart attack treatment and bone fracture repair Stem cells in treatment of different diseases ELISA, PCR, MICROARRAY-on-a-CHIP Hormonal diagnostics, metabolism, fertility, pre- and neonatal Tumourmarker Anaemia (Ferritin) Allergy (IgE- total and specific), Osteoporosis, thrombosis, sensitivity towards anticoagulants, sensitivity to antidepressants TORCH, HIV, niche diseases Conjugates, calibrators, recombinant proteins, antigens, allergens ASTRA BIOTECH GmbH Im Biotechnologiepark TGZ I 14943 Luckenwalde Germany Phone +49 3371 681 450 Fax +49 3371 681 451 info@astrabiotech.de www.astrabiotech.de Anna Fot (Business Manager) Alexandra Ghica-Cantacuzino (International Sales and Marketing)

atlasbiolabs ATLAS Biolabs GmbH Foundation: 2006 Employees: 12 ATLAS Biolabs GmbH is a leading provider of complex analyses in molecular genetics including microarray-based genomic services, targeted sequence capture, and next generation sequencing. Market Segments ATLAS Biolabs performs Genome-wide gene expression and SNP analyses Array CGH Comprehensive mutation profiling and other novel NGS applications for academic institutions, pharmaceutical and biotechnological enterprises, as well as for clinicians and registered doctors. The following services are provided by ATLAS Biolabs: Exome enrichment Next generation sequencing Genotyping Expression profiling Whole genome human SNP genotyping Molecular karyotyping Targeted sequence enrichment Raindance sequence enrichment Sample preparation Bioinformatics analysis and project management Methylation Oncocarta ATLAS Biolabs GmbH Friedrichstraße 147 107 Berlin Germany Phone +49 30 3198966 0 Fax +49 30 3198966 19 customer-support@atlas-biolabs.com www.atlas-biolabs.com Prof. Dr. Peter Nürnberg (CEO)

Attomol GmbH Foundation: 1997 Employees: 12 Development, production and distribution of IVD-marked diagnostic tests under Attomol brand or OEM Main technologies are protected by 5 patents Direct marketing in Germany Formation of an international distributor network is not yet finished Co-founder of the research community BioResponse e.v.: www.bioresponse.de Market Segments Molecular genetics Molecular diagnostics of pathogens Autoimmunodiagnostics LoopTag real time PCR or DNA-LINA strip tests: Mycobacteria, Bordetella, Borrelia, Mycoplasma Quicktype mutation assays: Thrombophilia, drug metabolism, lactose intolerance etc. Bead Assay: plex Anti-Nuclear-Antibody confirmation Antibody LINA strip tests: Anti-gangliosides, anti phospholipids Technologies: Real time PCR, multiplex technologies, bead assay Applications: Anti-lipid antibody detection, coagulation risk profiling Attomol GmbH Schulweg 6 OT Lipten 03205 Bronkow Germany www.attomol.de Dr. Werner Lehmann

BIOTECON Diagnostics GmbH BIOTECON Diagnostics was founded in 1998 and currently has 51 employees. Our expertise is microbiological service testing of food, beverage and pharmaceutical products. Our company focuses on the development of rapid and innovative detection systems for pathogenic, spoilage and genetically modified organisms based on real time PCR. Besides detection kits, the foodproof product line also includes kits for sample preparation. Today, as an international biotechnology company, biotecon Diagnostics develops, produces and markets these products. We foster a growing network of distributors as well as offer contract development and production to other biotech companies. Due to strong partnerships with food, beverage and pharmaceutical companies, BIOTECON Diagnostics is well aware of their current and future problems. Our experience lends to our strong capability to find new and economically interesting approaches to these existing and upcoming problems both in production and processing. As a small company, we maintain our flexibility to respond to industry concerns quickly and efficiently. Simply put, we provide desired solutions. Fotolia Sven Hoppe BIOTECON Diagnostics GmbH Hermannswerder 17 14473 Potsdam Germany Phone +49 331 2300 00 Fax +49 331 2300 299 bcd@bc-diagnostics.com www.bc-diagnostics.com Kornelia Berghof-Jäger, Ph. D. (CEO) Alois Schneiderbauer (CBO)

BioTeZ Berlin-Buch GmbH Foundation: 1992 Employees: 20 We understand ourselves as partners of biotechnological research, pharmaceutical industry and lab analysis for innovation and quality. Our Business Portfolio: In vitro-diagnostics: e. g. for therapeutical antibodies (TAB) to measure the interaction between TAB and antigens to optimize the treatment Customized synthesis of oligonucleotides (high level services) Support of mycotoxine and vitamin analysis; production of very effective immunoaffinity columns, ELISAs, and toxin and detection conjugates ELISA development, conjugation and labeling of biomolecules, other services Signal/Assay enhancement using our high-tech molecule (Polystrept R), e. g. for lateral flow tests Market Segments IVD development and production Oligonucleotid synthesis Immobilization of molecules ELISA development Feed and food analysis IVD development for the therapeutic antibodies: Enbrel, Avastin, Herceptin Aptamere development BioTeZ Berlin-Buch GmbH Haus 79 Robert-Rössle-Straße 10 13125 Berlin Germany Phone +49 30 94892130 Fax +49 30 9494509 info@biotez.de www.biotez.de Uwe Ahnert (Member of the board) Outstanding expertise in immunoassays. Own patents and IP: Signal enhancement by Polystrept R (highest immo bilization, outstanding biotin binding capacities) Coating of surfaces for binding biotinylated molecules Unique IVD technology for measuring therapeutic antibodies and antigen in patient serum Immobilisation of biomolecules, e. g. on surfaces and columns

Thermo Fisher Scientific, B r a h m s GmbH Thermo Scientific B R A H M S Biomarkers investigate, develop and manufacture novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With our high-quality immunodiagnostic tests for sepsis, cardiovascular, pulmonary, and cancer disorders as well as prenatal screening we contribute to the creation of a healthier future to the greatest advantage for medical professionals and patients. In Future simple and economic blood tests will be of great importance for an early detection and successful treatment of diseases. With our Know-How and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 65 countries worldwide and support their clinically and economically relevant decisions. On the basis of our completely owned patents and with help of more than 470 employees worldwide Thermo Scientific B R A H M S Biomarkers are leading in specific market places and therapeutic areas. Fully automated KRYPTOR platform with TRACE technology (TRACE = Time-Resolved Amplified Cryptate Emission) Radioimmunoassay Lumineszenzassay Enzymimmunoassay The aim of our basic research is to identify new biomarkers, with support by international cooperations and reputable research institution. Thermo Fisher Scientific B R A H M S GmbH Neuendorfstraße 25 16761 Hennigsdorf Germany Phone +49 3302 8830 Fax +49 3302 883100 info.brahms@thermofisher.com www.thermoscientific.com/brahms

BST Bio Sensor Technology GmbH Foundation: 1991 Employees: approx. 20 BST s history dates back to 1975 when a biosensor research group started at the Berlin Academy of Sciences. Already in 1982 the first European glucose analyzer based on a multi-way glucose biosensor could be launched successfully. Today, BST is market leader in multi-way biosensors in europe and an international operating company in e. g. Asia, Eastern and Western Europe. BST s core competence is the development and production of multi-way biosensors as well as instruments based on these multi-way biosensors for laboratory and POCT applications. In addition to that also all related consumables are developed, produced and marketed by BST. Market Segments POCT diagnosis of glucose and other metabolites based on multi-way biosensors Determination of glucose and other metabolites for clinical chemistry Diagnosis of training state of athletes (lactate analysis) Immobilising of biological recognition elements for usage in diagnostic tools Conception, development and production of: Multi-way biosensors for pmol/l to mmol/l concentrations Instruments based on multi-way biosensors (e. g. GLUKOMETER PRO, LAC PRO, LabTrend) All related consumables for the application of multi-way biosensors Development of potentiometric sensors based on thick film technology Development of minimal invasive glucose system BST Bio Sensor Technology GmbH Buchholzer Straße 55 61 13156 Berlin Germany Phone +49 30 7676731 0 Fax +49 30 7676731 28 info@bst-biosensor.com www.bst-biosensor.com Dr. Dorothea Zahn (Managing Director)

caprotec bioanalytics GmbH Foundation: 2006, start of building up operation in 2008 Employees: 30 caprotec bioanalytics GmbH has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures and samples in a targeted and directed manner. caprotec s Capture Compound Mass Spectrometry (CCMS) Technology is based on trifunctional Capture Compounds which enable capturing and isolating proteins based on their functionality CCMS is closing a technology gap between shotgun approaches and pull-down experiments thus addressing an unmet need in the proteomics community The company is commercializing the CCMS technology as kits for research applications and customized Capture Compounds in collaborations with pharmaceutical companies or academic research The focus is on investigating mechanisms of drug action and avoidance of toxicological effects of small molecule drugs Small molecule protein interactions Proteomics Signal transduction Protein kinases Market Segments Drug discovery Proteomics research Capture Compound Mass Spectrometry (CCMS) caprotec bioanalytics GmbH Volmerstraße 5 12489 Berlin Germany www.caprotec.com Prof. Dr. Hubert Köster caprokits caprobox capromag ImproMed

CellTrend GmbH Foundation: 1998 Employees: 8 CellTrend is a certified biotech and diagnostic company. We are offering services and products: Bioassays for drug research and development Cell culture testing Immunogenicity testing Development and production of immunoassays Market Segments Pharma/Biotech/Cosmetics Contract research Contract analysis Contract production Diagnostics CellTrend GmbH Im Biotechnologiepark TGZ 2 14943 Luckenwalde Germany Phone +49 3371 681 290 Fax +49 3371 681 312 info@celltrend.de www.celltrend.de Dr. Harald Heidecke (CEO) Mammalian cell culture Immunoassays for research and diagnostic Oncology Cardiovascular diseases Detection of autoantibodies Biomarker development

Chipron GmbH Foundation: 2004 Empoyees: <15 Chipron GmbH develops and manufactures DNA macroarrays on polymer supports. The company specializes in assay development for pathogen detection, mutation analysis and food analysis based on its proprietary LCD- Array platform. LCD-Array Kits for HPV typing, kras mutation analysis, detection of fungal or bacterial pathogens and meat species identification are distributed in over 15 countries through a network of distribution partners. Apart from catalogue products Chipron offers customized LCD-Array Kits for particular demands and has developed over 100 of such assays during the last 5 years for industrial and governmental customers. LCD-Array Kits are available as RUO or CE-IVD kits and as OEM products on demand. The minimal requirements for specific lab instrumentation in combination with the simple but comprehensive data readout by the SlideReader software make LCD-Arrays a very robust and economical solution for virtually any laboratory with experience in PCR. Market Segments DNA-based detection assays for human or veterinary pathogens, mutation analysis and food analysis major R&D-Topics DNA/PCR-based quick tests Chipron GmbH Eresburgstraße 22 23 12103 Berlin Germany Phone +49 30 78799470 Fax +49 30 78799499 info@chipron.com www.chipron.com Dr. Volker Heiser heiser@chipron.com PCR-based DNA macroarray kits for pathogen, species and mutation detection Non fluorescent data readout by transmission light scanning and slidereader software Scanner, centrifuge and analysis software

CONGEN Biotechnologie GmbH Foundation: 1998 Employees: > 25 CONGEN is specialized in food testing by molecular analysis based on DNA and RNA detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analysis by real time PCR. Due to our experience in this field, we have a worldwide unmatched competence. We are offering a complete package consisting of: Providing fully accredited service Full range of real time PCR kits for every real time PCR cycler Full range of kits and protocols for sample preparation Real time PCR core reagents (SureMaster and SureCyle ) 1 laboratory 1 Real time PCR training and full support for real time PCR CONGEN Biotechnologie GmbH Robert-Roessle-Straße 10 13125 Berlin Germany Phone +49 30 948935 00 Fax +49 30 948935 10 info@congen.de www.congen.de Our mission is to serve the food industry with an excellent service and with standardized and reliable test kits in order to realize highest possible food safety and food quality. The full spectrum of our analytical services and products is integrated in our program called: SureFood The SureFood program covers parameters in the application of GMO, allergen, pathogen, animal, plant detection. In all the above application fields CONGEN is an internationally highly recognized and accepted partner for service and real time PCR reagents. The quality of the analyses is assured by using validated methods. CONGEN is accredited according to the EN ISO 17025:2005. All kits are manufactured according to the ISO 9001:2008.

E.R.D.E.-AAK-Diagnostik GmbH Foundation: 2005 E.R.D.E.-AAK-Diagnostik GmbH is a diagnostics laboratory that offers the detection of diverse autoantibodies (agaab) in sera. Agonistic autoantibodies (agaab) are directed against cellu lar receptors, particularly those involved in heart function, blood pressure regulation and vascular diseases. AgAAB are frequently detected in patients with: DCM, Myocarditis: agaab against β1-adrenergic receptor and M2-muscerinergic receptor Hypertension: agaab against α1-adrenergic receptor Diabetes type 2: agaab against α1- and AT1-adrenergic receptor Dementia: agaab against α1- and β2-adrenergic receptor To determine the agaab-status different special analysis techniques are used. The prevalence of the different agaab in the different diseases varies from 30 to 90 %. Patients will benefit at a given agaab indication from a personalized, specific medicamentous therapy, which accounts for the agaab induced malfunction of receptors. E.R.D.E.-AAK-Diagnostik GmbH Biomedizinischer Forschungscampus Berlin-Buch Robert-Roessle-Straße 10 13125 Berlin Germany Phone +49 30 9489 2226 Fax +49 30 9489 2229 Mobile +49 16075375 bimmler@aak-diagnostik.de www.aak-diagnostik.de Mrs. Dipl.-Ing. Marion Bimmler The detection of the agonistic Autoantibodies (agaab) is realized by the following analysis techniques: ELISA (not functional): Detection of a single agaab BIOASSAY (functional): Analysis of all agaab of the sample CALCIUM (functional): Measurement of intracellular calcium transients

Epigenomics AG Foundation: 1998 Employees: 82 Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics lead product, Epi procolon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the US. The Company s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the US. Epi procolon (marketed in EU; in R&D for US) Epi prolung (marketed in EU) Pipeline with further products for colorectal, lung and prostate cancer Applications in early detection, diagnosis, prognosis, and drug response prediction All products based on proprietary DNA methylation technology Biomarker discovery and validation IVD development for EU and US (ISO 13485) Companion diagnostics R&D for pharma partners DNA methylation technologies Epigenomics AG Kleine Präsidentenstraße 1 10178 Berlin Germany Phone +49 30 24345 0 Fax +49 30 24345 555 contact@epigenomics.com www.epigenomics.com Dr. Achim Plum (Sen. VP Corporate Development)

Epiontis GmbH Foundation: 2003 Employees: Using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service as well as customized development of epigenetic assays. Market Segments Quality control for cell therapies Immunomonitoring Epigenetic markers Biomarkers Immunomonitoring service (fee for service) based on epigenetic markers for immune cells Assays for cell therapy quality control (contract development) Discovery of novel epigenetic markers Markers specific for particular cell types Future diagnostic (prognostic, predictive, monitoring) markers Epiontis GmbH Rudower Chaussee 29 12489 Berlin Germany Phone: +49 30 6392 3474 hoffmueller@epiontis.com www.epiontis.com Ulrich Hoffmüller (PhD, MBA, Chief Business Officer)

FILT Lungen- und Thoraxdiagnostik GmbH Foundation: 1992 Employees: 7 FILT Lung- and Thorax Diagnostic GmbH is developer and manufacturer of products with focus on Exhaled Breath Analysis and airways inflammation diagnostic for treatment management in Asthma and COPD. Our mission in FILT is to use the combined experiences in medical functional and laboratory diagnostic to generate innovative products to improve the early diagnostic of inflammatory diseases and its therapeutic management. Market Segments Pulmonology Asthma COPD POCD of inflammatory diseases Lung function diagnostic, specialized in fractionated breath collection and measurement of flows, volumes, pressures, gases and biomarkers for analytical evaluation of inflammatory diseases ECoScreen 2 (EBC Collector F) ECoCheck (EBC Analyser for H 2 O 2, ph, Lactat) FILT Lungen- und Thoraxdiagnostik GmbH Robert-Rössle-Straße 10 13125 Berlin Germany Phone +49 30 948924 Fax +49 30 948925 info@filt.de www.filt.de

GA Generic Assays GmbH Developing, manufacturing and distributing in vitrodiagnostic assays in the field of systemic autoimmunity like rheumatic diseases, autoimmune hepatitis, autoimmune neuropathies, vasculitis, autoimmune kidney diseases, gastroenterology and antiphospholipid syndrome (APS) Market leader for anti-asialoglycoprotein receptor ELISA (anti-asgpr) (autoimmune hepatitis) Inventor and market leader for APS antibody profiling by immunodot Inventor and market leader for anti-glycoprotein 2 ELISA (GP2) a new serological marker for Crohn s disease Manufacturing cell-based immunofluorescence assays like HEp2 cells, ANCA and Crithidia luciliae cells Operating worldwide New diagnostic markers for autoimmune neuropathies New diagnostic marker for gastroenterology Market Segments In vitro-diagnostics IFA (HEp2 cells, ANCA, Crithidia luciliae cells and tissue sections) ELISA Immunodot Rapid tests Latex tests GA Generic Assays GmbH Ludwig-Erhard-Ring 3 15827 Dahlewitz/Berlin Germany Phone +49 33708 9286 0 Fax +49 33708 9286 50 info@genericassays.com www.genericassays.com Dr. Christina Fritz (Head of Scientific Marketing)

GILUPI GmbH Foundation: 2006 Employees: 18 Several collaborations with various national and international medical universities International company with operations in Europe and the US Several positive ethical votes for clinical trials Proof of concept in vivo Awarded for a grant Medizintechnik Innovationswettbewerb 2007 of the BMBF Market Segments The inventions of the GILUPI GmbH are in the market area of molecular diagnostics. In the prenatal sector the market for screening for trisomy 21 is about 2,5 billion EURO. In the field of cancer for isolating rare tumorcells the market is about 1 billion EURO. GILUPI GmbH is developing, marketing, and selling innovative new nanotechnology-based medical devices to detect and monitor circulating rare blood cells, with a strong focus on the prenatal diagnostic and cancer diagnostic market One application of the new nanodetector device is in the area of prenatal diagnosis, e. g. for analysis of chromosomal aberrations such as that found in Down syndrome Another application is focusing on detecting and enriching rare circulating tumor cells (CTC) from the peripheral blood of cancer patients as markers of disease recurrence and efficacy of systemic cancer treatment Development of the functionalized structured medical wire (FSMW) Biomarker discovery and validation Development of antibodies GILUPI GmbH Am Mühlenberg 14476 Potsdam Germany Phone +49 331 58184782 www.gilupi.de Inga Kliem inga.kliem@gilupi.com Bild: Michael Kempf (fotolia.com)

GlucoMetrix AG GlucoMetrix AG was founded in 2001. It has 3 major subsidiaries that concentrate on different aspects of enhancing the quality of life for people suffering from diabetes. GlucoMetrix NIB GmbH develops medical devices for measuring blood sugar non-invasively, i. e. without puncturing the skin. GlucoMetrix PVS GmbH develops a new production method for insulin which promises a purer insulin with less side effects. GlucoMetrix Pharma VV GmbH develops, manufactures and markets medicinal products related to wound healing. These are particularly suited for diabetic wounds. Development of expression platforms for biomedical products Development of downstream purification methods BIOSept line of wound treatment products Opto-acoustical device to measure blood sugar non invasively (in collaboration with ETH Zurich) Immunological assay to determine glycated serum proteins (POC-assay; in collaboration with FHI BMT) Genetic predisposition for diabetes mellitus Cost-effective production methods for human insulin GlucoMetrix AG Am Mühlenberg 14476 Potsdam Germany info@glucometrix.de www.glucometrix.de P.P. Schikora (CEO)

Glycotope GmbH Foundation: 2001 Employees: 75 GLYCOTOPE is a leading biopharmaceutical company in the fields of glycomics and immunotherapeutics and one of the rare full service providers in the development of biologics. For proprietary and customers drug development programs Glycotope has established a business unit to perform immunomonitoring of clinical samples. Offered also as a stand-alone service to support clinical studies, the pharmacokinetic and dynamic characteristics of biotherapeutics and the immune status of patients are determined according to the GCLP guidelines. A variety of kits for quantitative characterization of the cellular immune status and responses is provided by Glycotope-Biotechnology. The kits are used by lab physicians, clinical research organisations and pharmaceutical R&D departments to better understand the activity of a number of immune cells that are relevant in a variety of diseases www.glycotope-bt.com. Design and conduct of immunomonitoring assays to support clinical development Diagnostic test kits based on flow cytometry procedures to measure various cell functions for functional characterisation of cellular immune response, T-cell analysis and characterisation of haematological relevant autoimmune diseases Glycotope GmbH Robert-Roessle-Straße 10 13125 Berlin Germany Phone +49 30 9489 2600 Fax +49 30 9489 2609 info@glycotope.com www.glycotope.com Dr. Hans Baumeister (Associate Director Clinical Immunomonitoring) Continuous development of project specific immunomonitoring assays

idoc Institute for Telemedicine and Health Communication GmbH & Co. KG Founded 2004 idoc provides innovative solutions within the fields of telemedicine. The institute combines medical expertise with professional IT and communication management. Market Segments 1telemedicine 1 1telesomnology 1 1telemonitoring 1 1healthcare 1 networks Dementia care Telemedical screening for sleep apnea Telemedical monitoring for diabetes, metabolic syndrom Telemedical data exchange application Telemedical network for multicenter studies Telemedical care support for dementia idoc Institute for Telemedicine and Health Communication GmbH & Co. KG Posthofstraße 8 14467 Potsdam Germany www.idoc.de Prof. Nikolaus Boehning 1telemedicine 1 1Prevention 1 Comprehensive medical services

ifp Institut für Produktqualität GmbH Founded 2004 Employees: 100 ifp Institut für Produktqualität GmbH is an independent competence centre for food, feed and pharmaceutical analytics, offering a complete range of services and diagnostic products. The combination of expert staff, state-of-the-art laboratory equipment and food diagnostics specifically developed and produced by ifp guarantees high-quality analyses and competent service. Several of ifp s innovative product lines are being successfully distributed worldwide by renowned cooperation partners. Microbiological test kits for the microtiter plate based determination of all water-soluble vitamins in food, pharmaceuticals and human serum Real-time PCR kits for the detection of food pathogens, GMO, allergens, plant and animal species ifp Institut für Produktqualität GmbH Teltowkanalstraße 2 12247 Berlin Germany Phone +49 30 7668600 Fax +49 30 76686050 info@produktqualitaet.com www.produktqualitaet.com Immunological assays for the rapid on-site detection and quantitative determination of food allergens Microtiter plate based enzymatic test kits for the photometric determination of sugars, organic acids and other metabolites in food Development of improved bioanalytical methods for food testing purposes 1 Strong involvement in funded research projects

in.vent DIAGNOSTICA GmbH Your Service Provider for Human Diagnostics Biomaterials of human origin Enhanced biobanking Protein chemistry Contract-based development of proteins and diagnostic tests Clinical studies and CE marking procedures for IVD Market Segments in.vent supplies you with Clinically defined sera and plasma with a worldwide unique variety of matrices Clinically defined human biomaterials like synovial fluid, CSF, etc. Stool, faecal samples Various tissues A great variety of proteins Services in development and manufacturing of diagnostic tests in.vent meets your individual requirements for the complete value chain which involves the areas of R&D, production and quality control with a strictly emphasis on reliability, quality and adherence to schedules. in.vent s procurement of human biomaterial is always strictly oriented towards individual projects as well as highest ethical standards and superior quality. All materials are procured exactly with the information you need and on your specific demand. in.vent s enhanced biobanking serves you with clinically characterized human biomaterials that match exactly your needs to build your customized biobank. in.vent s newest products are the execution of the laboratory part of clinical studies and of CE marking procedures. in.vent DIAGNOSTICA GmbH Neuendorfstraße 17 16761 Hennigsdorf Germany Phone +49 3302 55199 www.inventdiagnostica.de Dr. J.-M. Hollidt (Managing Director) jm.hollidt@inventdiagnostica.de We would be delighted finding solutions that fit you.

Institute Cardiac Diagnostics and Therapy (IKDT GmbH) Foundation: 2002 Employees: 8 IKDT is a leading laboratory worldwide in differential diagnostics of viral infections and inflammation of heart muscle tissue following the international recommendations. Three main topics will be covered for routine diagnostics: Histology Immunohistochemistry and Molecular virology IKDT is the only cardiological laboratory performing molecular diagnostics of endomyocardial biopsies in Germany which is accredited by College of American Pathologists (CAP) according to FDA guidelines. Customers for our biopsy diagnostics are hospital-affiliated institutions or private doctor offices. By its platform Innovative Diagnostics IKDT lab as one of the first service providers in Europe offers for customers the prompt access to two innovative research technologies and Taqman Low-Density-Arrays (Applied Biosystems) for gene expression studies or microrna profiling, and bead-based Luminex technology for multiplex measurement of cytokine and immunological profiles. Market Segments Molecular diagnostics and research in cardiology MicroRNA profiling in myocardial tissue and peripheral blood Gene expression studies in cardiac patients Autoantibodies in cardiac patients Mutation screening in patients with cardiomyopathy Institute Cardiac Diagnostics and Therapy (IKDT GmbH) Moltkestraße 31 12203 Berlin Germany info@ikdt.com www.ikdt.com www.innovative-diagnostics.eu Dirk Lassner, PhD (Managing Director) Services provided: Routine differential diagnostics of endomyocardial biopsies on cardiomyopathies Molecular diagnostic service

JPT Peptide Technologies GmbH Foundation: 2004 Employees: 45 Offices: Berlin, Boston, Brussels Collaborations: NIH, Duke University, Harvard Medical School (USA), Karolinska Institutes (Sweden), BioNTech AG (Germany) JPT Peptide Technologies (JPT) is an ISO 9001:2008 certified and GCLP audited global supplier and development partner for innovative peptide related immune monitoring tools, molecular diagnostics and biomarkers. JPT has developed several high-content peptide technologies that allow proteome spanning and multiplexed discovery, validation, quantification of biomarkers as well as monitoring humoral and cellular immune responses in disease progression and under therapeutic invention. Seromarker discovery, validation and quantification Development of diagnostic tools for immune monitoring and patient stratification Peptide discovery, qualification and optimization Market Segments Molecular and immune diagnostics Biomarker discovery and validation Vaccine and immunotherapy development PepStar TM Peptide microarray platform for seromarker discovery and immune monitoring PepSpot TM Ultra high-throughput peptide synthesis approach for proteome wide T-cell epitope discovery PepMix TM Peptide pool platform for profiling cellular immune responses SpikeTides TM Small scale peptide technique for biomarker quantification JPT Peptide Technologies GmbH Volmerstraße 5 12489 Berlin Germany Phone +49 30 6392 5500 Fax +49 30 6392 5501 info@jpt.com www.jpt.com

Labor Berlin Charité Vivantes Services GmbH Foundation: 20 The company is the service subsidiary of Europe s largest hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research facilities. Labor Berlin performs > 20 Mio analyses in clinical pathology per year; it is the exclusive laboratory partner of Charité Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9.000 in-house patients a day and over 800.000 out-patients per year. Very broad portfolio of routine diagnostic testing Individual patient services (health monitoring) Testing of new preclinical diagnostics systems (prototypes) High throughput testing under routine conditions of novel diagnostic platforms Co-development of new biomarkers with industrial partners Validation of new bioassays for ivd industry Design, realization and analysis of clinical studies for CROs, pharmaceutical industry, life science companies and research facilities Field tests of telemedical IT solutions Labor Berlin Charité Vivantes Services GmbH Augustenburger Platz 1 13353 Berlin Germany www.laborberlin.com Dr. Andreas Weimann andreas.weimann@laborberlin.com Florian Kainzinger florian.kainzinger@laborberlin.com Co-developing and establishing a fully automated platform for microbiological pathology Data collection on preanalytical systems Co-developing and establishing a routine tele haematological IT solution for linking 12 hospitals in Berlin

LGC Genomics GmbH Foundation: 1993 as AGOWA LGC Group acquires AGOWA in 2005 Rebranded and established in April 2010 as LGC Genomics Number of employees: 50 A division of the LGC Group, LGC Genomics delivers high quality services and products for DNA and genetic analysis and sample preparation including: Next generation sequencing DNA sequencing and library construction Nucleic acid extraction services DNA extraction products pharmacogenetics and diagnostic services. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards. Market Segments Pharmaceutical and biotechnical companies Private and public research organisations Medical institutions Nucleic acid preparation: Nucleic acid extraction service (DNA, RNA) Kits for nucleic acid preparation (medium/high throughput) LGC Genomics GmbH Ostendstraße 25 12459 Berlin Germany Phone +49 30 5304 2200 Fax +49 30 5304 2201 service@lgcgenomics.com www.lgcgenomics.com Dr. Steffen Krüger (Managing Director) Werner von Heimann (European Sales and Marketing Manager) Genomic services: Next generation sequencing (Roche/454 and Illumina HighSeq 2000) Re-sequencing of genes and/or genomic regions Library services Cloning and sequencing Identification of microorganisms Genotyping services Sanger DNA sequencing services

Limetec Biotechnologies GmbH Foundation: 2001 Employees: 20 Software development System integration Diagnostics for infectious diseases Analysis of genetic predisposition Market Segments Infectious diseases Pharmacogenomics Cardiology Biomarker identification and validation The company develops modern biomolecular methods and has brought already more than thirty innovative products on the market (CE marked products). High-speed and high-quality proof systems for the detection of bacteria and viruses Proof system for allelic discrimination detection for hereditary diseases High-sensitive and secure immunoblot for early detection of Lyme disease Software and device Creation of affordable communication solutions which connect ambulatory (out-patient) and stationary (in patient) care Limetec has developed lab@ccess, an innovative webbased platform for laboratory orders. This innovative system provides versatile information, supports data exchange with the lab and makes cost transparency possible by allowing analyses of economic indicators. Close-partnered project TERA-Diagnostic MRSA detection Allelic discrimination assays (TaqMan method) Detection of human antibodies against Borrelia Drug resistance of Mycobacterium tuberculosis Limetec Biotechnologies GmbH Ladeburger Straße 17 16321 Bernau Germany Phone +49 3338 694265 Fax +49 3338 764440 www.limetec-biotechnologies.de

Medipan GmbH Developing, manufacturing and distributing in vitrodiagnostic assays in the field of organ-specific autoimmunity like thyroid diseases and type 1 diabetes Market leader in type 1 diabetes diagnostic; Inventor and market leader of the AKLIDES System, first system for fully automatic evaluation for cell-based immunofluorescence tests Currently distributing AKLIDES -assays for diagnostic of systemic rheumatic diseases (Hep2-cells, ANCA and Crithidia) Regarding AKLIDES as a multiparameter platform we are developing a bead system (ANA and ANCA diagnostic) and assays for other indications European distributor of rapid tests (diabetes, liver function, kidney function, urinary tract infection) for the use at home Operating worldwide Market Segments In vitro-diagnostics ELISA RIA (Digital) IFA (Hep2 cells, ANCA and Crithidia) Bead assays Platform technology of AKLIDES System Bead assays Medipan GmbH Ludwig-Erhard-Ring 3 15827 Dahlewitz/Berlin Germany Phone +49 33708 4417 0 Fax +49 33708 4417 25 info@medipan.de www.medipan.de Dr. Christina Fritz (Head of Scientific Marketing)

-omics Technologies 1 Metanomics Health GmbH Metanomics Health a BASF Group company applies comprehensive Metabolite Profiling (metabolomics) with biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and xenobiotic metabolites in biological systems. The core expertise of Metanomics Health resides in discovery and validation of biomarkers. Market Segments Metanomics Health provides its services to pharmaceutical, diagnostics and nutrition companies. Technology applications include: Mechanism of action studies Mechanism of toxicity studies Translational and clinical biomarker development (e. g. PK/PD, patient stratification, efficacy and safety markers) Companion diagnostic development Cell culture and bioprocess optimization Metabolite profiling platform with more than 75 GC-MS and LC-MS/MS instruments Wide metabolite coverage via combination of unbiased and targeted platforms Unique tox mode of action prediction through MetaMap Tox database Excellence in systems correlation analysis of complex gene function relationships In cooperation with academic institutes and clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome, heart failure, prostate cancer and multiple sclerosis to mention a few. Metanomics Health GmbH Tegeler Weg 33 10589 Berlin Germany www.metanomics-health.de

MicroDiscovery GmbH Foundation: 2000 Employees: 16 MicroDiscovery develops software and bioinformatics solutions for diagnostics, personalized medicine and molecular biology research. The portfolio also includes biostatistical data analysis and data management. Efficient proprietary algorithms are the basis for customer specific software for in vitro-diagnostics and medical technology. Software solutions can be developed as CE-certified, FDA compliant (21 CFR part ) and ISO 62304- compliant. MicroDiscovery is DIN ISO 9001:2008 certified by TÜV Rheinland. major R&D-Topics Market Segments Bioinformatics Software development for in vitro-diagnostics and biomedical instruments Data analyses for clinical and biological requirements Software development: Customer-specific OEM software development, algorithm development as well as biochips analysis software Data analysis: NGS/HTS data analysis service and data mining Biostatistical analysis: Evaluation of clinical studies, assay validation and biomarker validation Data management: Database development and data integration Development of multiparameter diagnostics Biomarker in complex diseases Systems biology for medical applications MicroDiscovery GmbH Marienburger Straße 1 10405 Berlin Germany www.microdiscovery.de Dr. Arif Malik

Minerva Biolabs GmbH Foundation: 1999 Employees: 15 Minerva Biolabs GmbH is a leading biotechnology company for the development and production of molecular PCR-based IVD diagnostic and research kits for the detection of microbial contamination in biopharmaceuticals and cell cultures and human pathogens. In addition we offer a broad range of testing procedures and elimination services for the pharmaceutical and biotechnology industry. Our company is based in Berlin and operates worldwide via numerous distributors. To secure customers confidence, Minerva Biolabs has designed a strict quality management system that meets all requirements of the worldwide accepted quality standards ISO 9001 and ISO 13485. Market Segments Molecular biology Microbiology Diagnostics Contamination control Contamination control: Detection and elimination of microbiological contamination, disinfection Clinical diagnostics Water diagnostics PCR supplements Enzymes Genomic DNA extracts Quantification standards Development and production of qpcr assays and applications in molecular biology. Minerva Biolabs GmbH Köpenicker Straße 325, Haus 12 12555 Berlin Germany Phone +49 30 2000 4370 Fax +49 30 2000 4379 info@minerva-biolabs.com www.minerva-biolabs.com Dr. Dirk Vollenbroich (CEO)

peptides&elephants GmbH Foundation: 2001 Employees: 10, PhD: 3 Market Segments Synthesis technology made in Germany peptides&elephants We serve Peptides for your perfect satisfaction with quality, price and support. Our major PEP-LIPS products are high parallel customized peptide libraries and peptide pools. PEP-LIPS are approved for T Cell Stimulation Assays, Epitope Mapping, EliSpot Assays, Drug Discovery and Array Technology. The full range of Peptides and Peptidomimetica from the single to millions from linear to cyclic from short to overlong, from crude to high purity, from modified to labeled, from natural to non natural amino acids peptides&elephants are your faithful partner. peptides&elephants GmbH Am Mühlenberg 14476 Potsdam Germany Phone +49 331 505700 Fax +49 331 50570120 info@peptides.de www.peptides.de

PolyAn GmbH Foundation: 1996 Employees: 16 PolyAn is specialised in Molecular Surface Engineering (MSE) and Surface Molecular Imprinting (SMI). PolyAn s proprietary MSE-technology platform is used in the production of biochips, microparticles and nanoparticles as well as membranes. PolyAn s surface functionalisation optimises the performance of analytical processes by improving the signal-to-noise ratio, the reproducibility and also enabling new combinations of surface functionality and base material. PolyAn offers a range of surface functionalised consumables for multiplex diagnostics and LifeScience research: Functionalised microarray slides (both glass and plastic) and 96-well plates with 3D-reactive surfaces for DNA, aptamere, peptide and protein arrays. Fluorescence encoded PMMA microparticles (beads) for multiplex bead arrays and other applications. The beads are adapted to the most commonly used detection systems, e. g. flow cytometry, image cytometry and microscopy systems, respectively. PolyAn GmbH Rudolf-Baschant Straße 2 13086 Berlin Germany Phone +49 30 912078 0 Fax +49 30 912078 mail@poly-an.de www.poly-an.de Fridtjof Lechhart Based on extensive experience in research and development of surfaces PolyAn also offers tailor-made solutions for specific customer applications, e.g. surface modified tubes, membranes, sinter and fleece materials, as consumables for a wide range of applications in LifeScience and other industries.

Proteome Factory AG Foundation: 2000 Employees: 7 Proteome Factory is specialized in protein analysis, proteomics and development of multiplex MeCAT metal linked immunoassays. Contract research: Amino acid (de novo) sequencing of proteins & antibodies, protein sequence verification and identification, characterization of PTMs, SS bridges, glycopeptides, 2DE and MS-based host cell protein assays, quality control of proteins and peptides, protein quantitation Biomarker finding, proteomics, immuno-, phosphor-, membrane- proteomics: 2DE, itraq, MudPIT etc. Fee-for-Service: 2DE, protein identification, protein analysis, N-terminal AA sequencing, high resolution mass spectrometry, nanolc-esi-msms Development of MeCAT immuno and bioimaging assays Development of ultra-sensitive MeCAT multiplex assays for bioimaging and immuno assays R&D in allergy Proteomics Market Segments Immunoassay Contract research services MeCAT metal coded tagging reagents for ultrasensitive multiplex assays of proteins and antibodies FireSilver MS compatible gel silver staining de novo peptide sequencing software Sequit! Proteome Factory AG Magnusstraße 12489 Berlin Germany www.proteomefactory.com Dr. Christian Scheler

Provitro GmbH Foundation: 2001 Employees: 9 Provitro combines more than ten years of experiences in commercialisation of cell culture technologies, Tissue microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in vitrodiagnostics and state-of-the-art services but also with individual solutions for their specific requests. Provitro collaborates with distributors in UK, Switzerland, Italy, Austria and Eastern Europe. Market Segments Cell biological services Immunohistochemical services Pathomolecular services Certified in-process quality control systems (icon TMA) verifying the specificity of antibody reaction. Primary cell cultures and cell-type specific culture media Cytokines Immunohistochemical services: Antibody testing and target validation Tissue microarrays Pathomolecular services Provitro GmbH Charitéplatz 1 107 Berlin Germany www.provitro.de Dr. Manrico Paulitschke (CEO) Dr. Axel Koepenik (Senior manager of production and services, QA and sales)

SCIENION AG Foundation: 2000 Employees: 32 SCIENION is a Berlin and Dortmund-based company offering complete solutions for parallel bioanalytics and high throughput production/screening of microarrays in genomics and proteomics. The company is a renowned specialist for ultra low volume liquid handling, particularly for precious and sensitive compounds of biological or chemical origin. SCIENION s technology can easily be transferred from R&D feasibilities to large scale ISO certified high throughput production. Market Segments SCIENION is a life science company well positioned in the markets of ultra low volume liquid handling systems and microarray technologies, addressing the dynamically increasing needs for miniaturization and multiplex analyses. Products and services are targeted mostly for diagnostics, pharmaceuticals, veterinary, plant and food analytics and research. SCIENION offers hardware, consumables and services. The sciflexarrayers allow for non-contact and precise drop spotting in the pico- to nanoliter range as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, gly cans or for dispensing cells. Systems and software are characterized by its versatility, precision and robustness. SCIENION s service includes contract array manufacturing and development of tailor-made array applications on customer specific supports. SCIENION AG Volmerstraße 7 b 12489 Berlin Germany Otto-Hahn-Straße 15 44227 Dortmund Germany www.scenion.de Dr. Holger Eickhoff (CEO)

Seramun Diagnostica GmbH Foundation: 1992 with 2 scientists Qualified staff of 37 scientists and technicians Biopharmaceutical company with certified quality management system, DIN EN ISO 9001:2008 and DIN EN ISO 13485:2003 Development and production of ELISAs, Blots and LIAs for in vitro-diagnostics of infectious and autoimmune diseases Development and supply of host cell ELISAs for pharmaceutical companies worldwide, e. g. for purity control of influenca vaccines European market leader in development and production of ready-to-use substrates for enzyme mediated immunoassays like ELISAs, LIAs, dot and chip assays Development and production of protein stabilizers Market Segments Medical diagnosis laboratories (testkits) and IVD manufacturers (reagents) OEM production of CE-certified IVDs for various German distribution companies Distribution of CE-certified LIAs Production of monoclonal and polyclonal antibodies, purification and labeling Production of recombinant proteins Development of enzyme immunoassays Seramun Diagnostica GmbH Spreenhagener Straße 1 15754 Heidesee Germany www.seramun.com Prof. Dr. Tomas Porstmann Multiparameter assays Development of polymeric HRP conjugates Development of substrates for protein arrays

SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin Foundation: 1991 Employees: 60 The roots of SIFIN GmbH, founded in 1991 and based in Berlin, go back to the early 19 th century. Under Bismarck it bore the name Berliner Impfanstalt (Berlin Institute for Vaccinations) and became part of the Institut für Seuchenschutz (Institute for the Control of Epidemics), which became known as the Staatliches Institut für Immunpräparate und Nährmedien (State Institute for Immunopreparations and Culture Media) in 1966. In 1992, with the help of a private investor, the diagnostic divisions were continued and successfully developed. Market Segments Health Food SIFIN GmbH Berlin has many years practice in the development and production of in vitro medical devices: Bacteriological test reagents based on monoclonal antibodies, for use in detection and serotyping of bacterial enteritis pathogens such as Salmonella, Shigella, Yersinia, E. coli, including enterohaemorrhagic E. coli (EHEC) and E. coli relevant to veterinary medicine Blood grouping reagents based on SIFIN clones, test reagents (ready-to-use) and kits used for automated blood-grouping systems and Serafol bedside cards Culture media for different applications Contract manufacturing of monoclonal antibodies (mabs) for use in diagnostics Monoclonal antibodies: We offer partnership in R&D and production of mabs on a large scale Test sera for serotyping of E. coli relevant to veterinary medicine SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin Berliner Allee 317 321 13088 Berlin Germany Phone +49 30 927030 0 Fax +49 30 927030 30 info@sifin.de www.sifin.de Martina Vasel (Sales Director)

Signature Diagnostics AG Foundation: 2004 as a private German stock corporation High qualified and experienced team currently consists of 36 employees (18 work on prospective clinical studies and 9 in R&D and ISO 15189 clinical laboratory). Market Segments Oncogenomics Clinical oncology diagnostics Molecular diagnostics in cancer/blood screening Identification and validation of biomarker Proprietary products (will be launched in Germany in 20): DETECTOR C for screening of CRC in asymptomatic individuals PREDICTOR C for prognosis/progressions-free survival of diagnosed CRC patients Technlogies: Data mining Pathology Tissue collection Array-based technology (RNA expression, SNP profiling and DNA re-sequencing) Cancer indications: Colorectal, lung, breast and ovarian cancer Signature Diagnostics AG Hermannswerder 20 a 14473 Potsdam Germany Phone +49 331 2000 200 Fax +49 331 2000 209 www.signature-diagnostics.de Prof. Dr. André Rosenthal (CEO) Dr. Rainer Kramer (CBO)

Source BioScience imagenes GmbH Launch of diagnostics: 1996 Employees: ca. 130 Source BioScience is an international healthcare and life sciences group with a number of laboratories in the UK, Ireland and Germany undertaking a range of genomic and IHC testing. We undertake work for health services, academic institutions, pharmaceutical companies and biotech companies. Amongst the services we offer a range of diagnostic services. Our laboratories are GLP, GCP and CPA accredited and can handle formalin fixed tissue samples, wax blocks or preprepared slides. We are registered with the UK HTA (Human Tissue Authority) and the UK Care Commission. Immunohistochemistry: Including HER2, Gastric HER2 and ER/PR Mutation detection: Including KRAS, BRAF, EGFR, NRAS, PI3K Blood analysis: Including CTC s (circulating tumour cells), CEC and CYP2D6 FISH: Including HER2, Gastric HER2 (including BDISH) and EGFR HPV testing: Including genotyping and specific testing for oral cancer Histopathology: Pathologist reporting service using a panel of 60 UK-based specialist histopathologists Cytogenetics analyses: Detection of chromosome aberrations across the entire genome Aneuploidy screening: Polar body analysis for IVF treatments Next generation sequencing: Developing NGS-based methods for tumour mutation profiling Cytology Biomarker development Source BioScience 1 Orchard Place Nottingham NG8 6PX UK Phone +44 5 9739056 healthcare@sourcebioscience.com Source BioScience imagenes Robert-Rössle Straße 10 (Haus D 79) 13125 Berlin Germany Phone: +49 30 94892440 www.healthcare.sourcebioscience.com

STRATEC Molecular GmbH Foundation: 1992 Employees: 27 STRATEC Molecular (former Invitek GmbH) is a member of the STRATEC Biomedical group and is based in Berlin since 1992. The company is a globally active provider of timesaving proprietary reagent systems for nucleic acid sample stabilization and purification. In close collaboration with clients tailored products are developed for both manual and automated workflows in molecular diagnostics and biomedical research. As an EN ISO 13485:2003 + AC 2007 and EN ISO 9001:2008 certified company all STRATEC molecular products are subject to extensive quality control. STRATEC Molecular kits are developed and manufactured in compliance with in vitro-diagnostic EU Directive 98/79/ EC. DNA/RNA sample management Automation of molecular diagnostic sample preparation Non-chaotropic chemistry gentle nucleic acid sample preparation (more intact DNA) MSB Minimal salt binding (the fastest way to purify DNA fragments) RTP Ready to prep (prefilled lysis tube, reduced hands-on steps) PSP DNA sample stabilization (at RT in stool, saliva or swab samples) InviTrap Selective removal of DNA (pure RNA without DNase digestion) InviMag Magnetic beads (manual and automated DNA/RNA purification) RNAsure Viral RNA protection (stabilization for up to 6 month at RT) STRATEC Molecular GmbH Robert-Roessle-Straße 10 13125 Berlin Germany www.invitek.de Dr. Jens Beator (Managing Director)

Strix Diagnostics GmbH Foundation: 2006 Strix Diagnostics links potent new technologies with the requirements of medical technology and diagnostics in order to create innovative and market-focused solutions. Our expertise in CE-certified multiparameter analysis systems enables our customers to quickly and efficiently establish their multiparameter diagnostic application or other multiplex assays in the market. The product portfolio ranges from innovative microarray scanner and biochip readers to integrated in vitro-diagnostic units. Customer specific OEM solutions are based on our tried and tested devices. Market Segments IVD devices Microarrays Image analysis Classification systems Multiparameter and multiplex analysis systems Forward looking automation and user-friendly ergonomics TLR500, transmitted light microarray reader FR202, cost-efficient fluorescence slide reader FR102 MTP reads arrays in 96-plate wells StrixAluco image acquisition and analysis software OEM development Strix Diagnostics GmbH Cantianstraße 10437 Berlin Germany Phone +49 30 473722 18 Fax +49 30 473722 16 info@strix-diagnostics.de www.strix-diagnostics.de Dr. Dieter Beule

Surflay Nanotec GmbH Surflay Nanotec, founded in October 2008 in Berlin-Adlershof, has specialised in the coating of surfaces to functionalise colloidal as well as larger scale materials. The key technology of the start up with 8 employees is the patentprotected Layer-by-Layer (LbL) technology with charged polymers (polyelectrolytes). The combination of physicochemical functions and biological properties separated by nanometre-thick layers allows the unique modification of the surface. The areas of application are modern separating materials, substance encapsulation, enzyme immobilisation as well as sensory or diagnostic beads. Patents and expertise together with licensed patents form the basis for the development of innovative and market-oriented solutions. Market Segments Molecular diagnostics Point of care testing (fundamental research) Contrast agents Biocatalysis Separation and filtration Dyes and pigments Enzyme immobilization RNA/DNA technologies Contrast agents Products Functionalised beads (LbL Beads) LbL capsules Oligonucleotide beads LbL kits Microbubbles Labeled polymers Technologies Basic technology: Layer-by-Layer (LbL)-Technology with charged polymers Functionalization of surfaces DNA/RNA encapsulation technology Surflay Nanotec GmbH Schwarzschildstraße 8 (in the Technology Park at Adlershof) 12489 Berlin Germany Phone +49 30 63921764 Fax +49 30 6706919101 info@surflay.com www.surflay.com Dr. habil. Lars Dähne (Authorised Manager)

TIB MOLBIOL Syntheselabor GmbH Foundation: 1990 Employees: >50 TIB MOLBIOL started 1990 as the first German manufacturer of oligonucleotide primers and real time PCR probes (TaqMan, SimpleProbe and LightCycler hybridization probes, Molecular Beacons, Scorpions Primers, LNA containing probes). Our products are used in the fields of life science research, medical diagnostics, product quality assessment and environmental analysis. Our research unit has created more than 15,000 customer specific qpcr and typing assays (design@tibmolbiol.de). Since 2005 we provide LightMix Research Use and Diagnostic Kits for pathogen detection, hematology and cancer targets, clinical chemistry and pharmacogenetics testing and LightSNiP assays for general SNP typing. Market Segments Public Research Laboratories / Universities Medical Diagnostic Laboratories Pharmaceutical Industry Nucleic Acid Synthesis (DNA, LNA, RNA oligonucleotides) Fluorescence Detection in real time PCR Assay Development OEM production of kits and probes LightMix real time PCR Kits LightSNiP real time PCR Genotyping Assays TIB MOLBIOL Syntheselabor GmbH Eresburgstraße 22 23 12103 Berlin Germany www.tib-molbiol.de Olfert Landt Design, development and evaluation of novel real time PCR assays for any type of instrument (charges apply, please inquire)

Zentrum für molekulare Onkologie GmbH (Center for molecular Oncology) Foundation: 2008 Employees: 4 Innovative methods for diagnostic and therapy of tumor diseases Molecular genetics, determination of mutations (K-RAS, EGFR, PCA3, etc.) Markers for early detection of tumor diseases (Septin9, own projects) Chemosensitivity assay for prediction of chemotherapy Pathology Development of new biomarkers and analytical services for studies Mutation analysis by sequencing and real time PCR Mammalian cell culture Methods of a pathology lab Oncology Biomarker development Zentrum für molekulare Onkologie GmbH Im Biotechnologiepark TGZ 2 14943 Luckenwalde Germany Phone +49 3371 681 313 Fax +49 3371 681 312 info@molekulare-onkologie.eu www.molekulare-onkologie.eu Dr. Kai Schulze-Forster (CEO)

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 BAM Federal Institute for Materials Research and Testing BAM uses its competences to improve safety in technology and chemistry through research and development, testing, analysis, approvals, advice and information. It represents a co-partner and service provider to industry and commerce, policy makers and consumers alike. Its Working Group (1) Immunochemical Methods (head: Dr. Rudolf J. Schneider) deals with various antibodybased analytical methods Its Working Group (2) Fluorescence Spectroscopy (head: Dr. Ute Resch-Genger) works on the design, characterization and application of functional chromophore systems as well as the design and supply of certified standards, calibration tools and validation strategies for different fluorescence techniques Its Working Group (3) Surface and Thin Film Analysis (head: Dr. Wolfgang Unger) works on the development and application of methods for surface, thin film and micro analysis, including Quality Management, reference materials, metrology and standardization (DIN, ISO) Technologies 1 Platforms 1 Application Fields (1) Development of immunoassays (ELISA, other formats), development of antibodies, synthesis of haptens, conjugation, identity/purity check of immunochemicals (LC-MS/MS, HR-MS, MALDI-TOF/ MS, fluorescence, NMR, x-ray structure analysis, etc.); applications in environmental monitoring, clinical/ in vitro-diagnostics (2) Design and spectroscopic characterization of functional chromophores and optical probes based on different types of fluorophores (1) Quality assurance with immunoassays, better screening methods for hybridoma selection (2) Development of signal amplification and multiplexing strategies, screening methods for labels, development of methods for the relative and absolute measurement of signal-relevant properties of different types of fluorescent labels and probes (3) Development of valid methods of surface chemical analysis, marker free read out of microarrays, selfassembled monolayers BAM Federal Institute for Materials Research and Testing Branch Adlershof Richard-Willstätter-Straße 12489 Berlin Germany (1) Dr. Rudolf J. Schneider Phone +49 30 8104 51 rudolf.schneider@bam.de (2) Dr. Ute Resch-Genger Phone +49 30 8104-34 ute.resch@bam.de Branch Fabeckstraße Unter den Eichen 44-46 12203 Berlin Gemany (3) Dr. Wolfgang Unger Phone +49 30 8104-1823 wolfgang.unger@bam.de www.bam.de (3) Surface chemical analysis (XPS, AES, SIMS, FTIR, WCA) for characterization of biomaterials and diagnostic tools (functional organic surfaces, microarrays)

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Charité Center for Diagnostic and Preventive Laboratory Medicine The Charité Center for Diagnostic and Preventive Laboratory Medicine comprises the disciplines of the Charité Universitätsmedizin Berlin active in the field of in-vitrodiagnostics including pathology, laboratory medicine & clinical chemistry, microbiology, virology, hygiene, and foren sic medicine. The Center provides a wide range of services for R&D and comprehends almost all scientific expertises in the field of in-vitro-diagnostics. The institutes of pathology, hygiene and forensic medicine also provide the complete range of services for healthcare. Diagnostic services of laboratory medicine & clinical chemistry, microbiology, and virology are provided by Labor Berlin Charité Vivantes GmbH (q.v.). Technologies 1 Platforms 1 Application Fields Tissue-based histopathological diagnostics Molecular genetics Biochemistry/ Clinical chemistry Cell-based assays DNA/RNA technologies Bioanalytics (Proteome, genome, and glycome analysis) Micobiological/Virological methods Forensic analyses The Charité Center for Diagnostic and Preventive Laboratory Medicine aims at the development of new efficient diagnostic processes and the identification of disease causes. Areas of research include Molecular cancer research (cancerogenesis, new biomarkers, DNA/RNA-based assays for diagnosis, therapy and prognosis) Glycome research (new biomarkers for oncology, autoimmune disease, stem cells) Molecular mechanisms of inflammation Complex microbial ecosystems in inflammatory bowel disease; microbial biofilms Epidemiology of nosocomial infections, hantavirus infections Mechanisms and post-mortem diagnosis of sepsis Genetic risk stratification of rheumatic diseases Antibody targeted enzyme prodrug therapies and immunotoxines Diagnosis of hereditary and acquired thrombophilia Charité Center for Diagnostic and Preventive Laboratory Medicine Charité Universitätsmedizin Berlin Campus Virchow-Klinikum Augustenburger Platz 1 13353 Berlin Germany www.charite.de/charite/charitecentren/uebersicht_der_ centren/cc_5_diagnostische_und_praeventive_labormedizin Prof. Dr. med. Rudolf Tauber (Medical Director) rudolf.tauber@charite.de

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 German Institute of Human Nutrition (DIfE) Potsdam-Rehbruecke The mission of the German Institute of Human Nutrition (DIfE) is to conduct experimental and clinical research in the field of nutrition and health, with the aim of understanding the molecular basis of nutrition-dependent diseases, and of developing new strategies for prevention, treatment, and nutritional recommendations. Technologies 1 Platforms 1 Application Fields A broad spectrum of experimental and epidemiological methods. Investigation of the genetic and pathophysiological basis of insulin resistance and type 2 diabetes Evaluation of the associations between diet, lifestyle, biochemical, and genetic markers and risk of type 2 diabetes, obesity, cardiovascular diseases and cancer Research on the role of dietary factors in the pathogenesis of nutrition-dependent diseases Molecular and biochemical characterization of the sense of taste Elucidation of the influence of gastrointestinal microbiota on human health German Institute of Human Nutrition (DIfE) Potsdam Rehbruecke Member of the Leibniz Association Arthur-Scheunert-Allee 4 6 14558 Nuthetal Germany Phone + 49 33200 88 335 Fax + 49 33200 88 503 presse@dife.de www.dife.de Dr. Gisela Olias

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Fraunhofer Heinrich Hertz Institute Innovations for the digital future in the field of modern communication systems and digital media and services are the key concern of all research and development work carried out by the Heinrich Hertz Institute. Technologies 1 Platforms 1 Application Fields The fields of expertise covered by the Fraunhofer Heinrich Hertz Institute range from optical communication networks, systems and components, mobile broadband systems, electronic imaging technologies through to broadband inhouse networks and optical sensor technologies. Key areas in which the Fraunhofer Heinrich Hertz Institute works include video and audio coding and transmission, 2D and 3D image signal processing, mixed reality displays, 3D displays, human/machine interfaces, information management and photo and video archiving/retrieval, and novel optical sensors based on our long-standing experience in optical communication technology. Life Science R&D-Topics include: Video retrieval and analysis (EDP-assisted comparison of individual clinical images) Wireless endoscopy Touch-free control of devices in operating theatres Radio sensor networks (e.g. for the capturing of diagnostic body function data) Photoacustic sensors detecting and measuring traces of gases Label-free optical sensors for bio analytics (integrated optical evanescence sensors including optical micro resonators) General Topics are: Communication networks (fixed and wireless) Image processing (modelling, coding, advanced displays) Cutting-edge interfaces (touchless control systems, high-end 3D without glasses) Integrated optoelectronic technology Fraunhofer Institute for Telecommunications Heinrich Hertz Institute Einsteinufer 37 10587 Berlin Germany Phone +49 30 31002 427 michael.witte@hhi.fraunhofer.de Michael Witte

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Fraunhofer Institute for Applied Polymer Research IAP The Fraunhofer IAP specializes in the research and development of all types of polymer applications. Polymers synthesized from fossil oil as well as biopolymers from renewable raw materials find their applications. Working areas cover the synthesis of novel polymers, derivatization of existing biopolymers, chemical analytics, physical and structure characterization, and processing Companies and partners are supported in finding customized solutions for innovative and sustainable materials, processing aids, and processes Areas of application are manifold, and partners come from various industries such as electronics and optics, medicine, pharmacy, cosmetics, and environmental or waste water technology Technologies 1 Platforms 1 Application Fields Polymer synthesis, polymerization and modification Specialized polymers for biomedical applications Nanoparticles with special functions and labels Non-fouling surfaces and biomolecule immobilization Switchable surfaces for cell culture Development and optimization of innovative and sustainable materials, processing aids and processes Smart bioresponsive (protein responsive), biocompatible and thermoresponsive polymers Biomedical surface modification Biofunctional nanoparticles Fraunhofer Institute for Applied Polymer Research IAP Geiselbergstraße 69 14476 Potsdam-Golm Germany www.iap.fraunhofer.de Dr. Erik Wischerhoff Phone +49 331 568 1508 erik.wischerhoff@iap.fraunhofer.de

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Fraunhofer Institute for Biomedical Engineering Branch Potsdam Fraunhofer IBMT develops products and applications in cooperation or in contract with the industry. In Potsdam, the work concentrates on bioanalytics and focuses on the following topics: Molecular bioanalytics and bioelectronics Nanobiotechnology and nanomedicine Cellular biotechnology and biochips Metabiobanks Cell-free biosynthesis Technologies 1 Platforms 1 Application Fields In agreement with our philosophy Technologies that fit to life, various micro- and nanosystems are developed as tools for life sciences and medicine. ivd-platform: Platform for in vitro-diagnostics Applications based on Lab-on-Chip System: Integration of all steps of a biochemical assay from sample preparation to analysis Modular platform for development and production of in vitro-diagnostics Multiparameter and microarray technologies Suitable for various samples and matrices Support on materials selection, surface treatment and biomolecule coupling Spotting technologies for preparation of arrays Readout systems and biosensors Fibre optic biosensor with fluorimetric detection Real time detection, ultra-sensitive and quantitative readout Fibre optic sensor disposable Label-free detection Electrochemical readout Electrodes Sensor-actor molecules and autonomous biosensors Assay development Biomarker validation Microfluidic systems Biomimetic materials Others: Cell-free protein synthesis, cryophyllic algae Fraunhofer Institute for Biomedical Engineering (IBMT) Am Mühlenberg 13 14476 Potsdam Germany Phone +49 331 58187 101 Fax +49 331 58187 199 www.ibmt.fraunhofer.de Dr. Stephanie Schwarz stephanie.schwarz@ibmt.fraunhofer.de ivd-platform soeren.schumacher@ibmt.fraunhofer.de www.ivd-plattform.fraunhofer.de

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Humboldt University of Berlin Research Center ImmunoSciences, Charité Systems Immunology Lab The Systems Immunology Lab was established in the Department of Biology at the Humboldt University Berlin in 2002. In winter 2006, it additionally became affiliated with the newly founded Research Center ImmunoSciences at the Charité Universitätsmedizin Berlin. During these years, the Systems Immunology Lab hosted varying numbers (5 8) of academic staff and graduate students from widely different scientific backgrounds, ranging from mathematics and physics to biotechnology and molecular genetics. Research at the Systems Immunology Lab is decidedly inter disciplinary, including laboratory-based fundamental science and computational modeling. Projects are carried out in collaboration with partners in industry, universities and clinics. Technologies 1 Platforms 1 Application Fields Random sequence peptide microarray technology Statistical immunoglobulin sequence analysis Semi-automated confocal image processing and analysis Deterministic and stochastic modeling, machine learning data analysis and optimal control theory Serological diagnostics of human brain tumors and renal allograft rejection using random sequence peptide microarrays Development of bioinformatic analysis tools for identification of mutations relevant to affinity maturation of antibodies Assessment of dynamic changes in cellular composition of lymphatic tissue structures by large-scale confocal imaging and mathematical modeling Systems Immunology Lab Research Center ImmunoSciences Hessische Straße 3 4 105 Berlin Germany m.orguil@biologie.hu-berlin.de www.sysimm.eu Dr. Michal Or-Guil

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 IHP gmbh INNOVATIONS FOR HIGH PERFORMANCE MICROELECTRONICS IHP is an institute of the Leibniz Association. It develops silicon-based high-frequency technologies, circuits and systems for the wireless and broadband communication. The institute employs a staff of 280 people from 20 countries. Technologies 1 Platforms 1 Application Fields IHP develops and runs a platform of 0.25/0.13 µm SiGe BiCMOS technologies with heterobipolar transistors up to 300 GHz cut-off frequency and additional modules such as integrated LDMOS and MEMS (microelectromechanical systems) in the institute s pilot line. Besides for wireless and broadband communication, IHP also provides innovations for biotechnology and medicine, aerospace, automotive industry, industrial automation and photonics. General Topics are: Wireless systems and applications (wireless sensor networks & Gigabit WLAN) RF circuits (integrated mm-wave circuits, broadband mixed-signal circuits and low power frontends) Technology platform for wireless and broadband communication Materials for micro- and nanoelectronics (e. g. for THz devices) IHP GmbH Innovations for High Performance Microelectronics/Leibniz-Institut für innovative Mikroelektronik Im Technologiepark 25 15236 Frankfurt (Oder) Germany Phone +49 335 5625 0 Fax +49 335 5625 300 ihp@ihp-microelectronics.com www.ihp-microelectronics.com Prof. Wolfgang Mehr (Scientific Director) Medical R&D-Topics include: Body area networks for life sciences System development for point of care diagnostics and telemedicine Sensing and short-range wireless transmission of medical data up to Gigabit data rates Microelectronic circuits & systems including embedded BioMEMS

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Max Delbrück Center for Molecular Medicine The Max Delbrück Center for Molecular Medicine (MDC) is a major biomedical research institute in Berlin. Our mission is to translate discoveries from basic research into applications to improve the prevention, diagnosis, and treatment of major human diseases. Scientists, students & technical staff: 1.150 Annual institutional budget: 61 m Annual extramural funding: 25 m Member of the Helmholtz Association Technologies 1 Platforms 1 Application Fields With a deep knowledge of the molecular basis of disease, researchers at the MDC are well placed to identify biomarkers and develop new assays and technologies. The MDC holds patents on biomarkers e. g. for cardiac diseases, cancer metastasis and acute kidney injury which will be developed in collaboration with third parties into clinical applications. Close collaboration with the clinics, especially the Charité, facilitates swift translation of the latest science from bench to bedside. The technology transfer partner of the MDC is Ascenion (www.ascenion.de). Cardiovascular & metabolic disease Cancer Nervous system disorders Max Delbrück Center for Molecular Medicine Berlin-Buch Robert-Rössle-Straße 10 13092 Berlin Germany Phone +49 30 9406 3478 cquensel@mdc-berlin.de www.mdc-berlin.de Dr. Christina Quensel (Scientific Coordinator)

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Functional Protein Analysis Group Department of Vertebrate Genomics at the Max Planck Institute for Molecular Genetics Expertise in identification and validation of (auto) antibodies as biomarkers for disease classification Pathway analysis and modelling Establishing alternative detection systems for biomolecules Relative quantification of proteins and posttranslational modifications Immobilisation of biomolecules (DNA, antibodies, proteins, peptides, small molecules) onto microarrays Technologies 1 Platforms 1 Application Fields Generation of low density (up to 1.000 spots) microarrays, e. g. peptide and reverse protein microarrays Different types of spotter (e. g. piezo spotter) Biacore instrument Protein-DNA and protein-protein interactions Miniaturisation of protein-based assays Determination and characterization of the kinetics of interactions (assoziation, dissoziation and equilibrium constant) Serum profiling Pathway analysis with reverse protein microarrays Alternative detection methods for biomolecules in miniaturized formats Protein interactions Max Planck Institute for Molecular Genetics Dr. H. Seitz Head of Functional Protein Analysis Group Phone +49 331 58187 208 seitz@molgen.mpg.de www.molgen.mpg.de/research/lehrach Prof. Dr. Hans Lehrach Director Head of Department of Vertebrate Genomics Max Planck Institute for Molecular Genetics Ihnestraße 63 73 14195 Berlin Germany

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Department of Biomolecular Systems at the Max Planck Institute of Colloids and interfaces Elucidating the role of complex carbohydrates involved in biological processes of medical relevance Employing molecular tools created by synthetic chemistry Understanding recognition events involving glycans that control cell growth, cell differentiation, cell-cell interactions, bacterial attachment and signaling events involving the extracellular matrix Technologies 1 Platforms 1 Application Fields Automated oligosaccharide synthesis Glycan microarrays Nanoparticles and colloidal polymers development of carbohydrate-based vaccines Serum analysis for carbohydrate-based biomarkers Development of carbohydrate-based vaccines against hospital-acquired bacterial infections, fungi and protozoan parasites Synthesis and biological activity of oligosaccharides, proteoglycans and glycosylphosphatidylinositols (GPIs) Impact of complex oligosaccharide structures on inflammatory processes Glycoproteins as diagnostic markers Synthesis of sequence-defined neoglycopolymers and their use for biomedical applications Department of Biomolecular Systems at the Max Planck Institute of Colloids and Interfaces Arnimallee 22 14195 Berlin Germany Phone +49 30 83859301 peter.seeberger@mpikg.mpg.de Prof. Dr. Peter H. Seeberger (Director Head of Department of Biomolecular Systems)

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Physikalisch-Technische Bundesanstalt Working Group 8.32 Flow Cytometry and Microscopy PTB is the national metrology institute providing scientific and technical services. The specific tasks of the working group Flow Cytometry and Microscopy concern the Determination of reference measurement values for measurands of the complete blood count, i. e. concentrations of erythrocytes, leukocytes and platelets, haemoglobin concentration and haematocrit value Measurement of reference values for particle concentration in suspensions or particle number in lyophilized samples Development of reference measurement procedures and reference instruments for cell counting in body fluids based on flow cytometry and microscopy including quantification of fluorescence Investigation of flow-cytometric and quantitative microscopic procedures for quality assessment in regenerative medicine Quantification of amplification in polymerase chain reaction (PCR) Accumulation of rare cells applying magnetic activated cell sorting (MACS) and flow cytometric cell sorting (FACS) Process development for rare cell detection in body fluids, e. g. endothelial cells in blood Data analysis and uncertainty determination for flow cytometric, microscopic and PCR applications Development of microfluidic devices for flow cytometric analyses Physikalisch-Technische Bundesanstalt Abbestraße 2 12 10587 Berlin Germany joerg.neukammer@ptb.de www.ptb.de Dr. Jörg Neukammer Picture: Photo of a micro-fluidic chip (left) for flow cytometric identification of immunologically stained T-lymphocytes (right, Ly-T h/i :T-helper/inducer lymphocytes, Ly-T s : T-suppressor lymphocytes, M: monocytes). The micro-fluidic chip was developed in cooperation with the Technical University Berlin, Fachgebiet Mikro- und Feingeräte)

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 Technical University of Applied Sciences Wildau The research interests of the Biosystems Technology Institute focus mainly on the analysis of electrochemical characteristics of biomolecules on metal and carbon electrodes, sensor developments and the determination of binding affinities of biomolecules and their interactions with modified surfaces. Characterization of conductive and switchable polymers for application as signal transducers in the detection of bioaffine binding partners Analysis of polymer films for interface applications of redox enzymes and the detection of heterogeneous electron transfer processes Development of sensors for free radicals (e. g. NO, O - 2 ) with protein-modified electrodes Development of multiprotein assemblies on electrodes for analytical applications Optical and mass-sensitive detection of toxins, virus and bacteria Utilization of nanoparticles (quantum dots, metal and silica nanoparticles, carbon nanotubes) for electrochemical and optical sensors Detection of DNA and DNA-binding with electrochemical DNA chips Protein chips Technologies 1 Platforms 1 Application Fields Voltammetry Surface plasmon resonance (SPR) Quarz crystal microbalance (QCM/QCMD) Ellipsometry, dynamic light-scattering Electrical impedance spectroscopy Fluorescence and FT-IR spectroscopy Nanoparticle synthesis Enzymatic systems Redox proteins DNA and aptamers Antibody characterization Biosensors Technical University of Applied Sciences Institute of Biosystems Technology Bahnhofstraße 1 15745 Wildau Germany Phone +49 3375 508 456 Fax +49 3375 508 458 flisdat@th-willdau.de www.th-wildau.de/lisdat Prof. Dr. rer. nat. habil. F. Lisdat

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 University of Applied Sciences Lausitz Department of Biotechnology The Lausitz University of Applied Sciences was founded in 1991 as a classical engineer education center and has a strong tendency in scientific research. In vitro-diagnostics and bio analytics was taken up in 2000 and is well integrated in the Lausitz University concept as a main research topic in medical diagnostics, biotechnology and life science. Technologies 1 Platforms 1 Application Fields Assay and technology development Bead-based protein and nucleic acid analysis Chemo/biosensors and corresponding technologies Protein modification and purification Image-based detection of autoimmune antibodies Cultivation and manipulation of primary cell cultures Cell lines designed for screening and production purposes Assay development Multiplex bead PCR/Hybridization array Cell- and bead-based diagnostic assays for autoimmune diseases Automatic identification of infection patterns of bacteria In vitro and in vivo citrullination and purification of protein antigens Design of cell lines suitable for screening of musculoskeletal tissue diseases Enzymatics and assays for citrullination, folding and protein degradation Electrochemical chemotransistors as transducers for biosensors SPR-biosensors with internal referencing Cell lines with targeted overexpression of various autoantigens EXPRESS platform University of Applied Sciences Lausitz Department of Biotechnology Grossenhainerstraße 57 01968 Senftenberg Germany Phone +49 3573 85 910 www.hs-lausitz.de Christian.Schroeder@hs-lausitz.de Prof. Dr. Christian Schröder

science Basic Research 1 Identification and Validation of Biomarkers 1 Assay Development 1 Technology Development 1 University of Potsdam The University of Potsdam is the major university in the federal state Brandenburg. Within the Potsdam research network pearls the university is linked to over 20 research facilities in the greater area of Potsdam. At the university s Institute of Biochemistry and Biology the following workgroups do research in the field of in vitro-diagnostics and bioanalytics: The research group Integrated Protein Chips for Point of Care Diagnostics ipoc (head: Dr. habil. Axel Warsinke) developed a platform technology for small and fast protein microarrays, which later can be used in hand-held units in a medical practice for example. The research group Antibody-Technologies (head: Dr. Katja Heilmann) works on new immunization and selection strategies for the production of monoclonal antibodies. For that a work station for the retrieval of monoclonal antibodies is available. The research group Analytical Biochemistry (head: auxilary Prof. Dr. Ulla Wollenberger) works on the development of applications of bioanalytical systems. Direct electron transfer and electrode design for direct protein electrode communication are studied using cytochromes, oxygenases, peroxidases and molybdoenzymes. Molybdoenzymes are studied in collaboration with the group Molecular enzymology (head: Prof. Dr. Silke Leimkühler). Work station for the retrieval of monoclonal antibodies. Photo: University Potsdam/Fritze University of Potsdam Am Neuen Palais 10 14469 Potsdam Germany Phone +49 331 977 1474 presse@uni-potsdam.de Birgit Mangelsdorf (Spokesperson) Public Relations and Information Service

The Capital Region Berlin-Brandenburg Facts, Services, Strategic Business Advantages More for Your Investment Berlin-Brandenburg offers investors the best financial support available in Europe. Investment subsidies are granted in the form of direct payments. The support programs created for these measures combine funds from the EU, the German federal government and the states of Berlin and Brandenburg. Large companies in the capital region can receive investment subsidies of up to 30 percent, while medium-size companies receive up to 40 percent and small companies up to 50 percent. 1 2 3 High Quality of Living The region combines the international flair of the Berlin metropolis with the charming countryside and historical treasures of the state of Brandenburg. The capital region also has a vibrant club scene, a long list of major cultural events, more than 170 museums, 150 stages and 500 palaces, churches and parks. Recreational activities such as golf, horseback riding, water sports and aviation are just some of the wide variety of activities to choose from. The overall cost of living, working and commuting is significantly lower than in other metropolitan regions. Investing Made Easy The capital region s two business development agencies, Berlin Partner GmbH and the ZAB Brandenburg Economic Development Board, provide comprehensive support during the setting-up of your company s operations in the region: professional, quick, with no red tape, free of charge and confidential.»» Business Info: Facts and figures on the Berlin-Brandenburg business region»» Personnel: Support in recruiting and training new staff»» Real Estate: Assistance in locating property for sale or rent»» Financing: Guidance on subsidy and financing opportunities»» s to government agencies, banks, chambers of commerce, associations and business networks www.brandenburg-invest.com www.businesslocationcenter.de/lifesciences_en 4 Berlin-Brandenburg An attractive location 1 Potsdamer Platz 2 Brandenburger Tor 3 Wissenschaftspark Potsdam-Golm 4 Potsdam Park Sanssouci Zentrum für Molekulare Diagnostik und Bioanalytik Berlin-Brandenburg TSB Innovationsagentur Berlin GmbH Fasanenstraße 85 10623 Berlin Germany Tel.: +49 30 318622 17 Fax: +49 30 318622 22 hahne@zmdb.de www.zmdb.de ZukunftsAgentur Brandenburg GmbH Team Healthcare Industry/Life Sciences Steinstraße 104 106 14480 Potsdam Germany Tel.: +49 331 6603 000 Fax: +49 331 6603 840 info@zab-brandenburg.de www.zab-brandenburg.de Berlin Partner GmbH Team Life Sciences Ludwig Erhard Haus Fasanenstraße 85 10623 Berlin Germany Tel.: +49 30 39980 0 Fax: +49 30 39980 239 info@berlin-partner.de www.berlin-partner.de

Imprint ZMDB Mai 20 Publisher Design Zentrum für Molekulare Diagnostik und Bioanalytik (ZMDB) TSB Innovationsagentur Berlin GmbH Fasanenstraße 85 10623 Berlin Germany www.zmdb.de supiran.de Proofreader Yvonne Frank, Berlin Print Photos schlesener.de Potsdamer Platz: Matthias Fischer Brandenburger Tor: Berlin Partner/FTB-Werbefotografie Wissenschaftspark Potsdam-Golm: Lutz Hannemann Potsdam Park Sanssouci: Böttcher_PTM